Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 11-12, 2011, Pages 1255-1268

  Gisbert, J P ^a   Calvet, X ^b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ANTIBIOTIC RESISTANCE; CLINICAL PROTOCOL; DRUG DOSE REGIMEN; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SPAIN; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREND STUDY;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; SPAIN; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 81355146380     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04887.x     Document Type: Review

References (102)

1. McColl KE,. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-604.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
3. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
4. Gisbert JP, Calvet X, Gomollon F, Mones J,. [Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference]. Med Clin (Barc) 2005; 125: 301-16.
5. Caselli M, Zullo A, Maconi G, et al. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007; 39: 782-9.
6. Chey WD, Wong BC,. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
7. Graham DY,. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272-7.
8. Megraud F,. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 1278-82.
9. Megraud F,. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
10. Graham DY, Lu H, Yamaoka Y,. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
11. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000; 95: 3393-8.
12. Vakil N, Lanza F, Schwartz H, Barth J,. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107.
13. Janssen MJ, Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA,. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 613-24.
14. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL,. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-64.
15. O'Connor A, Gisbert JP, McNamara D, O'Morain C,. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010; 15 (Suppl 1): 46-52.
16. Graham DY, Lu H, Yamaoka Y,. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008; 68: 725-36.
17. Castro-Fernandez M, Lamas E, Perez-Pastor A, et al. Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Rev Esp Enferm Dig 2009; 101: 395-8. 9-402.
18. Graham DY, Shiotani A,. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321-31.
19. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM,. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-54.
20. Gisbert JP, Mur M, Boixeda D, et al. [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. Med Clin (Barc) 1997; 108: 524-9.
21. Gisbert JP, Boixeda D, de Argila CM, Bermejo F, Redondo C, de Rafael L,. Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics. Eur J Gastroenterol Hepatol 1997; 9: 957-62.
22. Perez Mota A, Alberdi JM, Pita L, et al. Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. Rev Esp Enferm Dig 1997; 89: 879-84.
23. Rodrigo Saez L, Fernandez Cadenas F, Lomo Montero J, Garcia Calero C, Garcia Saavedra L,. [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. Rev Esp Enferm Dig 1997; 89: 146-7.
24. Baena Diez JM, Sancho Perpinan A, Lopez Mompo C, Rams Rams F, Jimenez Navarrete S, Comet Jaumet D,. [Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care]. Aten Primaria 1998; 22: 547-51.
25. Comet R, Calvet X, Navarro M, Garcia N, Sanfeliu I,. [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. Gastroenterol Hepatol 1998; 21: 81-3.
26. Forne M, Viver JM, Esteve M, et al. Randomized clinical trial comparing two-one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. Am J Gastroenterol 1998; 93: 35-8.
27. Garrido A, Lepe JA, Guerrero FJ, Palomo S,. [Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity]. Enferm Infec Microbiol Clin 1998; 16: 471-3.
28. Gisbert JP, Boixeda D, Bermejo F, et al. [Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. Rev Clin Esp 1998; 198: 655-9.
29. Martin Mir ML, Val J, Fuentes J, et al. [Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule]. Gastroenterol Hepatol 1998; 21: 432-6.
30. Calvet X, Lopez-Lorente M, Cubells M, Bare M, Galvez E, Molina E,. Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment Pharmacol Ther 1999; 13: 781-6.
31. Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F,. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80.
32. Garcia-Romero E, del Val A, Garrigues V, et al. [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. Gastroenterol Hepatol 1999; 22: 1-6.
33. Gisbert JP, Boixeda D, Aller R, et al. [Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]. Med Clin (Barc) 1999; 112: 161-5.
34. Banos F, Madridejos R, Cabezas C, Burrull M, Lafuente C, Morera R,. [Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study]. Med Clin (Barc) 2000; 114: 441-3.
35. Castellote J, Porta F,. [Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori]. Med Clin (Barc) 2000; 115: 118-9.
36. Bujanda L, Sanchez A, Iriondo C, Santos A, Cosme A, Munoz C,. [Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days]. An Med Interna 2001; 18: 361-3.
37. Gisbert JP, Hermida C, Pajares JM,. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? Hepatogastroenterology 2001; 48: 1383-8.
38. Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 2001; 115: 1002-3.
39. Mones J, Rodrigo L, Sancho F, et al. Helicobacter pylori eradication versus one-year maintenance therapy: effect on relapse and gastritis outcome. Rev Esp Enferm Dig 2001; 93: 372-89.
40. Baena JM, Lopez C, Hidalgo A, et al. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol 2002; 14: 291-6.
41. Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection-a randomized trial. Aliment Pharmacol Ther 2002; 16: 1261-7.
42. Elizalde JI, Pique JM, Moreno V, et al. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. Aliment Pharmacol Ther 2002; 16: 577-86.
43. Gaig P, Garcia-Ortega P, Enrique E, Papo M, Quer JC, Richard C,. Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. Allergol Immunopathol (Madr) 2002; 30: 255-8.
44. Bermejo F, Boixeda D, Martin De Argila C, et al. Healing of Helicobacter pylori gastric ulcers: only eradication matters. Rev Esp Enferm Dig 2003; 95: 625-8.
45. Vazquez Romero M, Boixeda de Miquel D, Valer Lopez-Fando MP, Albeniz Arbizu E, Gonzalez Alonso R, Bermejo San Jose F,. Intestinal metaplasia: evolution after Helicobacter pylori eradication and influence in the success of eradicating therapy. Rev Esp Enferm Dig 2003; 95: 781-4.
46. Gisbert JP, Cruzado AI, Garcia-Gravalos R, Pajares JM,. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study. Hepatogastroenterology 2004; 51: 303-8.
47. Gonzalez Carro P, Legaz Huidobro ML, Perez Roldan F, et al. [Efficacy of Helicobacter pylori eradication in non-ulcer dyspepsia]. Med Clin (Barc) 2004; 122: 87-91.
48. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP,. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005; 100: 1696-701.
49. Gisbert JP, Dominguez-Munoz A, Dominguez-Martin A, Gisbert JL, Marcos S,. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am J Gastroenterol 2005; 100: 1935-40.
50. Ruiz Garcia A, Gordillo Lopez FJ, Hermosa Hernan JC, Arranz Martinez E, Villares Rodriguez JE,. [Effect of the Helicobacter pylori eradication in patients with functional dyspepsia: randomised placebo-controlled trial]. Med Clin (Barc) 2005; 124: 401-5.
51. de Artaza Varasa T, Valle Munoz J, Perez-Grueso MJ, et al. [Effect of Helicobacter pylori eradication on patients with functional dyspepsia]. Rev Esp Enferm Dig 2008; 100: 532-9.
52. Sanfelix Genoves J, Pereiro Berenguer I, Jimeno Bernard R, et al. [Helicobacter pylori: 6-day triple therapy in duodenal ulcer]. Aten Primaria 1998; 21: 517-21.
53. Lopez-Brea M, Domingo D, Sanchez I, Alarcon T,. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrob Chemother 1997; 40: 279-81.
54. Lopez Bartolome O, Moran Vasallo A, Ramirez Armengol JA, Picazo de la Garza JJ,. [Microbiologic diagnosis of Helicobacter pylori and its resistance to antibiotics]. Rev Clin Esp 1998; 198: 420-3.
55. Perez-Trallero E, Montes M, Larranaga M, Arenas JI,. How long for the routine Helicobacter pylori antimicrobial susceptibility testing? The usefulness of the string test to obtain Helicobacter for culture. Am J Gastroenterol 1999; 94: 3075-6.
56. Ferrero M, Ducons JA, Sicilia B, Santolaria S, Sierra E, Gomollon F,. Factors affecting the variation in antibiotic resistance of Helicobacter pylori over a 3-year period. Int J Antimicrob Agents 2000; 16: 245-8.
57. Garcia Diaz E, Romero Gomez M, Vargas J, Guil A, Bernal S, Castro M,. Prevalencia y significado clínico de resistencia antibiótica de Helicobacter pylori. Rev Esp Enferm Dig 2000; 92: 651-5.
58. Rojas Feria M, Suarez Barrenechea AI, Conejo Gonzalo C, Hergueta Delgado P, Romero Castro R, Herrerias Gutierrez JM,. Resistance of Helicobacter pylori to antimicrobial treatment in a Seville hospital catchment area. Rev Esp Enferm Dig 2000; 92: 793-8.
59. Lopez-Brea M, Martinez MJ, Domingo D, Alarcon T,. A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother 2001; 48: 295-7.
60. Toro C, Garcia-Samaniego J, Carbo J, et al. [Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid]. Rev Esp Quimioter 2001; 14: 172-6.
61. Cuchi Burgos E, Forne Bardera M, Quintana Riera S, Lite Lite J, Garau Alemany J,. [Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment]. Enferm Infecc Microbiol Clin 2002; 20: 157-60.
62. Gomollon F, Santolaria S, Sicilia B, et al. [Helicobacter pylori resistance to metronidazole and clarythromicin: descriptive analysis 1997-2000]. Med Clin (Barc) 2004; 123: 481-5.
63. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
64. Buzas GM, Jozan J,. First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. World J Gastroenterol 2006; 12: 5311-9.
65. Buzas GM,. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16: 3865-70.
66. Choi YS, Cheon JH, Lee JY, et al. [The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years]. Korean J Gastroenterol. 2006; 48: 156-61.
67. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I,. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 28: 1960-6.
68. Cho DK, Park SY, Kee WJ, et al. [The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy]. Korean J Gastroenterol 2010; 55: 368-75.
69. Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-year first-line eradication Rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 2010; 47: 53-8.
70. Pajares Garcia JM, Pajares-Villarroya R, Gisbert JP,. [Helicobacter pylori infection: antibiotic resistance]. Rev Esp Enferm Dig 2007; 99: 63-70.
71. Fischbach L, Evans EL,. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57.
72. Gisbert JP, Maria Pajares J,. [Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review]. Med Clin (Barc) 2001; 116: 111-6.
73. Pérez-Trallero E, Ramírez-Lázaro MJ, Villar H, et al. Resistencia de Helicobacter pylori a diversos antibióticos: un estudio multicéntrico español. Gastroenterol Hepatol 2011; 34: 236.
74. Megraud F, Kist M, Lopez Brea M, et al. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008-2009. Gastroenterology 2011; 140 (Suppl.1): 1715.
75. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP,. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
76. Fallone CA,. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000; 14: 879-82.
77. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002; 8: 388-96.
78. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006; 55: 1711-6.
79. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 13-24.
80. Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FD, Howard AJ,. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8. BMJ 1999; 319: 1239-40.
81. Lazaro Bengoa E, Madurga Sanz M, de Abajo Iglesias FJ,. [Trends in antibiotic consumption in Spain, 1985-2000]. Med Clin (Barc). 2002; 118: 561-8.
82. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-9.
83. Loivukene K, Maaroos HI, Kolk H, Kull I, Labotkin K, Mikelsaar M,. Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clin Microbiol Infect 2002; 8: 598-603.
84. Toracchio S, Marzio L,. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-5.
85. Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003; 36: 368-71.
86. Simsek H, Balaban YH, Gunes DD, Hascelik G, Ozarlan E, Tatar G,. Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter 2005; 10: 360-1.
87. Chisholm SA, Teare EL, Davies K, Owen RJ,. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 2007; 12: E3-4.
88. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-10.
89. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19: 409-14.
90. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM,. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999; 43: 511-5.
91. Wolle K, Leodolter A, Malfertheiner P, Konig W,. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-9.
92. Kalach N, Serhal L, Asmar E, et al. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis 2007; 59: 217-22.
93. Gisbert JP,. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med 2011: in press.
94. Gisbert JP, Pajares JM,. Review article: Helicobacter pylori"rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-57.
95. Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S,. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003; 35: 357-61.
96. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA,. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-25.
97. Gisbert JP, Calvet X,. Review article: Non-bismuth quadruple (concomitant) therapy for Helicobater pylori eradication. Aliment Pharmacol Ther 2011; 34: 604-17.
98. Gisbert JP, Marcos S, Gisbert JL, Pajares JM,. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001; 13: 1303-7.
99. de Boer WA, Tytgat GN,. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol 2001; 13: 1281-4.
100. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M,. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-9.
101. Ford A, Moayyedi P,. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003; 17 (Suppl B): 36B-40B.
102. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F,. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-62.